WT1 and chronic myelogenous leukemia, BCR-ABL1 positive: The third trial is being conducted by Morris and colleagues in the UK using autologous gene-modified T cells with a HLA-A*02:01-restricted WT1-specific TCR in combination with lymphodepletion for treatment of AML/CML (ClinicalTrials.gov.